Several studies suggest the cross-talk between the ARID1A and PI3K pathways in clear cell ovarian cancer and have shown that synthetic lethality by targeting EZH2 in ARID1A-mutated tumors correlates with inhibition of PI3K/AKT signaling (22, 25). This evidence concerns the gene ARID1A and ovarian clear cell cancer.